Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · IEX Real-Time Price · USD
26.76
+0.82 (3.16%)
Jul 22, 2024, 1:53 PM EDT - Market open
3.16%
Market Cap 2.16B
Revenue (ttm) 360.91M
Net Income (ttm) -134.74M
Shares Out 82.31M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 445,290
Open 26.29
Previous Close 25.94
Day's Range 25.56 - 26.76
52-Week Range 16.95 - 49.50
Beta 1.87
Analysts Buy
Price Target 42.20 (+57.7%)
Earnings Date Aug 6, 2024

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301,... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2020
Employees 507
Stock Exchange NASDAQ
Ticker Symbol BEAM
Full Company Profile

Financial Performance

In 2023, BEAM's revenue was $377.71 million, an increase of 520.01% compared to the previous year's $60.92 million. Losses were -$132.53 million, -54.16% less than in 2022.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $42.2, which is an increase of 57.70% from the latest price.

Price Target
$42.2
(57.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Beam Therapeutics Announces Transition of Chief Financial Officer

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its...

7 days ago - GlobeNewsWire

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the firs...

26 days ago - GlobeNewsWire

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting i...

5 weeks ago - GlobeNewsWire

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius...

7 weeks ago - GlobeNewsWire

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

2 months ago - GlobeNewsWire

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

2 months ago - GlobeNewsWire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated

2 months ago - GlobeNewsWire

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

4 months ago - GlobeNewsWire

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...

5 months ago - GlobeNewsWire

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024

5 months ago - GlobeNewsWire

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...

6 months ago - GlobeNewsWire

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data ...

7 months ago - GlobeNewsWire

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...

7 months ago - GlobeNewsWire

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appo...

7 months ago - GlobeNewsWire

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh...

9 months ago - GlobeNewsWire

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

9 months ago - GlobeNewsWire

Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam's Cash Runway to the Second Half of 2026 Beam to Receive $250 Million in Combined Upfront Paymen...

9 months ago - GlobeNewsWire

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year

9 months ago - GlobeNewsWire

Beam Therapeutics to cut 20% of workforce as part of restructuring plan

Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructuring plan.

9 months ago - Reuters

Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026

Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash runway into 2026. The Cambridge, Mass.

9 months ago - Market Watch

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation

9 months ago - GlobeNewsWire

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models First Preclinical Data for BEAM-302 Demonstrate I...

11 months ago - GlobeNewsWire

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States BEAM-201 Represent...

11 months ago - GlobeNewsWire

Beam Therapeutics to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...

11 months ago - GlobeNewsWire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort

1 year ago - GlobeNewsWire